MA42828A - Plate-forme d'échafaudage à noeud de cystine - Google Patents

Plate-forme d'échafaudage à noeud de cystine

Info

Publication number
MA42828A
MA42828A MA042828A MA42828A MA42828A MA 42828 A MA42828 A MA 42828A MA 042828 A MA042828 A MA 042828A MA 42828 A MA42828 A MA 42828A MA 42828 A MA42828 A MA 42828A
Authority
MA
Morocco
Prior art keywords
cystine knot
scaffolding platform
scaffolding
platform
cystine
Prior art date
Application number
MA042828A
Other languages
English (en)
Inventor
Xinxin Gao
Rami Hannoush
Harini Kaluarachchi
Aaron NILE
Cameron Noland
Yingnan Zhang
Lijuan Zhou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA42828A publication Critical patent/MA42828A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/63—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
MA042828A 2015-09-15 2016-09-15 Plate-forme d'échafaudage à noeud de cystine MA42828A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562219063P 2015-09-15 2015-09-15

Publications (1)

Publication Number Publication Date
MA42828A true MA42828A (fr) 2018-07-25

Family

ID=57068206

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042828A MA42828A (fr) 2015-09-15 2016-09-15 Plate-forme d'échafaudage à noeud de cystine

Country Status (23)

Country Link
US (7) US10428125B2 (fr)
EP (1) EP3350215A1 (fr)
JP (2) JP7166916B2 (fr)
KR (1) KR20180052718A (fr)
CN (3) CN114591422A (fr)
AR (1) AR106032A1 (fr)
AU (2) AU2016323445B2 (fr)
BR (1) BR112018002263A2 (fr)
CA (1) CA2996006A1 (fr)
CL (2) CL2018000668A1 (fr)
CO (1) CO2018002510A2 (fr)
CR (1) CR20180169A (fr)
HK (1) HK1253318A1 (fr)
IL (2) IL257399B (fr)
MA (1) MA42828A (fr)
MX (1) MX2018002922A (fr)
MY (1) MY190552A (fr)
PE (1) PE20181293A1 (fr)
PH (1) PH12018500577A1 (fr)
RU (1) RU2770384C2 (fr)
TW (1) TWI799366B (fr)
UA (1) UA125505C2 (fr)
WO (1) WO2017049009A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2019233605A1 (fr) * 2018-06-08 2019-12-12 BioNTech SE Compositions et méthodes pour le diagnostic et le traitement du cancer
KR20230023727A (ko) 2020-06-11 2023-02-17 제넨테크, 인크. 나노지단백질-폴리펩티드 접합체 및 조성물, 시스템, 및 이의 사용 방법

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US918814A (en) 1907-10-30 1909-04-20 Handy Mfg Company Funnel.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
EP0752248B1 (fr) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Application thérapeutique d'anticorps chimériques et radio-marqués contre l'antigène à differentiation restreinte des lymphocytes B humains pour le traitement du lymphome des cellules B
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997043316A1 (fr) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Molecules physiologiquement actives a demi-vies prolongees et methode d'utilisation de ces dernieres
BR9908226A (pt) 1998-02-25 2000-10-24 Lexigen Pharm Corp Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
CA2341029A1 (fr) 1998-08-17 2000-02-24 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
EP1268544A2 (fr) 2000-03-31 2003-01-02 Institut Pasteur Peptides inhibant l'angiogenese induite par le vegf (facteur de croissance endotheliale), polynucleotides codant pour ces peptides et leurs procedes d'utilisation
CA2410912A1 (fr) 2000-06-01 2001-12-06 Amgen, Inc. Polypeptides a noeud de cystines: molecules "cloaked-2" et leurs utilisations
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
DE60239868D1 (de) 2001-06-12 2011-06-09 Univ Johns Hopkins Med Reservoirvorrichtung für die intraokulare arzneimittelabgabe
WO2003029275A2 (fr) 2001-10-03 2003-04-10 Regeneron Pharmaceuticals, Inc. Peptides anti-angiogeniques
GB0130738D0 (en) 2001-12-21 2002-02-06 Serono Internat S A Protein
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
WO2005110374A1 (fr) 2004-04-30 2005-11-24 Allergan, Inc. Systemes de distribution de medicaments intraoculaires contenant un agent therapeutique, une cyclodextrine et un composant polymere
DE102005002978B4 (de) 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
WO2006078161A1 (fr) 2005-01-24 2006-07-27 Pepscan Systems B.V. Composes liants, composes immunogenes et composes peptidomimetiques
US20060204548A1 (en) 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
JP2008546821A (ja) 2005-06-29 2008-12-25 ロゼリ、 パトリツィア Ｖｅｇｆ受容体を制御する化合物、およびその使用
CN101583370A (zh) * 2005-09-27 2009-11-18 阿穆尼克斯公司 蛋白质药物及其用途
EP1929073A4 (fr) 2005-09-27 2010-03-10 Amunix Inc Produits pharmaceutiques proteiques et utilisations de ceux-ci
TW200732347A (en) 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use
US7918814B2 (en) 2006-05-02 2011-04-05 Georgia Tech Research Corporation Method for drug delivery to ocular tissue using microneedle
WO2008045252A2 (fr) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Peptides modifies de liaison aux integrines
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
WO2008070479A2 (fr) 2006-12-01 2008-06-12 Allergan, Inc. Procédé pour déterminer des emplacements oculaires optimaux pour des systèmes d'administration de médicament
CA2697099C (fr) 2007-08-21 2018-02-20 Board Of Regents, The University Of Texas System Melange thermocinetique pour des applications pharmaceutiques
AU2009228158B2 (en) 2008-03-27 2014-02-27 Zymogenetics, Inc. Compositions and methods for inhibiting PDGFRbeta and VEGF-A
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
EP2349327A4 (fr) * 2008-10-23 2012-11-28 Massachusetts Inst Technology Engagement dirigé de récepteurs fc activateurs
WO2010060748A1 (fr) 2008-11-03 2010-06-03 Molecular Partners Ag Protéines de liaison inhibant l’interaction du récepteur vegf-a
CA3045436A1 (fr) 2009-01-29 2010-08-05 Forsight Vision4, Inc. Administration d'un medicament dans le segment posterieur
US8778888B2 (en) 2009-11-06 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
US20110207653A1 (en) 2009-12-21 2011-08-25 Adrian Raiche Microparticle Encapsulated Thiol-Containing Polypeptides Together with a Redox Reagent
EP2515864A4 (fr) 2009-12-23 2013-09-11 Psivida Inc Dispositifs d'administration à libération prolongée
US8339139B2 (en) * 2010-01-29 2012-12-25 Infineon Technologies Ag System and method for testing a circuit
US10844106B2 (en) 2010-11-08 2020-11-24 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
KR20200125765A (ko) * 2011-02-18 2020-11-04 아사나 바이오사이언시스 엘엘씨 아미노인단 화합물 및 통증 치료에서 그것의 용도
US9187553B2 (en) 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
EP2890389A1 (fr) 2012-08-28 2015-07-08 Novartis AG Utilisation d'un antagoniste du vegf dans le traitement de maladies de prolifération vasculaire oculaire
GB201218278D0 (en) * 2012-10-11 2012-11-28 Cyclogenix Ltd Translocating peptide
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺

Also Published As

Publication number Publication date
RU2770384C2 (ru) 2022-04-15
JP2018533912A (ja) 2018-11-22
AU2016323445A1 (en) 2018-03-01
JP7166916B2 (ja) 2022-11-08
TW201717993A (zh) 2017-06-01
US20200231636A1 (en) 2020-07-23
PH12018500577A1 (en) 2018-10-15
AU2021204400B2 (en) 2023-02-02
US20200325187A1 (en) 2020-10-15
MX2018002922A (es) 2018-06-07
IL257399A (en) 2018-04-30
RU2018113442A3 (fr) 2020-02-17
US20170129927A1 (en) 2017-05-11
CL2020001781A1 (es) 2020-10-23
US11155586B2 (en) 2021-10-26
EP3350215A1 (fr) 2018-07-25
CO2018002510A2 (es) 2018-05-31
IL257399B (en) 2022-08-01
AU2021204400A1 (en) 2021-07-22
KR20180052718A (ko) 2018-05-18
US20230174596A1 (en) 2023-06-08
TWI799366B (zh) 2023-04-21
US20180291069A1 (en) 2018-10-11
CR20180169A (es) 2018-04-24
BR112018002263A2 (pt) 2018-09-18
US20200115424A1 (en) 2020-04-16
WO2017049009A1 (fr) 2017-03-23
US11078243B2 (en) 2021-08-03
MY190552A (en) 2022-04-27
HK1253318A1 (zh) 2019-06-14
US10428125B2 (en) 2019-10-01
CA2996006A1 (fr) 2017-03-23
IL294568A (en) 2022-09-01
CL2018000668A1 (es) 2018-07-20
US11407794B2 (en) 2022-08-09
AR106032A1 (es) 2017-12-06
RU2018113442A (ru) 2019-10-16
US10696721B2 (en) 2020-06-30
CN114805528A (zh) 2022-07-29
US20200140498A1 (en) 2020-05-07
AU2016323445B2 (en) 2021-04-01
UA125505C2 (uk) 2022-04-13
WO2017049009A8 (fr) 2018-02-22
CN108026162B (zh) 2022-04-05
CN114591422A (zh) 2022-06-07
PE20181293A1 (es) 2018-08-07
CN108026162A (zh) 2018-05-11
JP2022130481A (ja) 2022-09-06

Similar Documents

Publication Publication Date Title
MA42036A (fr) Analogues nucléosidiques 5'-substitués
MA46180A (fr) Analogues de l'amyline
MA48596A (fr) Caractéristique d'inertie
FR3033707B3 (fr) Simulateur d'escalier
MA42771A (fr) Chaussure perméable à l'air
HK1253318A1 (zh) 胱氨酸結支架平台
DK3512518T3 (da) Buprenophinformuleringer med langvarig frigivelse
JP1630897S (ja) 手袋
IT201700090331A1 (it) "lopemide"
IT201700071679A1 (it) Remembebe'
MA51199A (fr) Agents d'imagerie
UA38213S (uk) Респіратор
UA37072S (uk) Респіратор протиаерозольний
IT201700103032A1 (it) Moschettone
UA34620S (uk) Іграшка - конструктор «мост»
ITUA20163709A1 (it) "presentosa3d"
FR3036257B3 (fr) "chaussure"
UA32431S (uk) Стрем'янка
UA34504S (uk) Упаковка для пальчаток «vitlux»
UA34505S (uk) Упаковка для пальчаток «vitlux»
ITUB201551290U1 (it) Ovie' oviel
FR3035837B1 (fr) Plaque d'immatriculation
UA34747S (uk) Кріпильний вузол
UA33779S (uk) Розгортка упаковки для пальчаток «o.o.o.ambulansvit»
UA30584S (uk) Нитрилові рукавиці (4015190000)